Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Fostamatinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK known ✓ | P43405 | 13/20 | 1.00 |
| ▸ | PTK2 | Q05397 | 4/20 | 1.00 |
| ▸ | PLK4 | O00444 | 3/20 | 1.00 |
| ▸ | RET | P07949 | 3/20 | 1.00 |
| ▸ | FLT3 | P36888 | 3/20 | 1.00 |
| ▸ | MAPK8 | P45983 | 3/20 | 1.00 |
| ▸ | MAPK9 | P45984 | 3/20 | 1.00 |
| ▸ | AURKB | Q96GD4 | 3/20 | 1.00 |
| ▸ | AURKA | O14965 | 2/20 | 1.00 |
| ▸ | STK16 | O75716 | 2/20 | 1.00 |
| ▸ | MST1R | Q04912 | 2/20 | 1.00 |
| ▸ | TNK1 | Q13470 | 2/20 | 1.00 |
| ▸ | IKBKE | Q14164 | 2/20 | 1.00 |
| ▸ | MAP3K11 | Q16584 | 2/20 | 1.00 |
| ▸ | ADCK1 | Q86TW2 | 2/20 | 1.00 |
| ▸ | PIP4K2C | Q8TBX8 | 2/20 | 1.00 |
| ▸ | NEK9 | Q8TD19 | 2/20 | 1.00 |
| ▸ | IRAK3 | Q9Y616 | 2/20 | 1.00 |
| ▸ | LATS1 | O95835 | 1/20 | 1.00 |
| ▸ | BRDT | Q58F21 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fostamatinib SCHEMBL1201371 | 1.00 | SYK (1.00) | SYKPTK2PLK4RETFLT3 | |
| Fostamatinib SCHEMBL16820327 | 0.99 | SYK (0.99) | SYKPTK2PLK4RETFLT3 | |
| Fostamatinib SCHEMBL22164570 | 0.99 | SYK (0.99) | SYKPTK2PLK4RETFLT3 | |
| Fostamatinib SCHEMBL28519986 | 0.99 | SYK (0.97) | SYKPTK2PLK4RETFLT3 | |
| Fostamatinib SCHEMBL12904057 | 0.97 | SYK (0.93) | SYKPTK2PLK4RETFLT3 | |
| Fostamatinib SCHEMBL16820330 | 0.96 | SYK (0.92) | SYKPTK2PLK4RETFLT3 | |
| SCHEMBL2627479 | 0.96 | SYK (0.92) | SYKPTK2PLK4RETFLT3 | |
| SCHEMBL12906324 | 0.96 | SYK (0.92) | SYKPTK2PLK4RETFLT3 | |
| SCHEMBL10167983 | 0.96 | SYK (0.92) | SYKPTK2PLK4RETFLT3 | |
| SCHEMBL20227102 | 0.95 | SYK (0.91) | SYKPTK2PLK4RETFLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 3623 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12629363-B2 | Prophylaxis and treatment of angioedema | PHARVARIS GMBH (CH) | 2026-05-19 | — | — | US | claimed |
| US-20260130856-A1 | LIPOSOME COMPOSITIONS FOR DELIVERY OF COMPOUNDS AND METHODS THEREOF | NANOTECH PHARMA INC (US) | 2026-05-14 | — | — | US | claimed |
| EP-4741395-A1 | NOVEL COMPOUND SENSITIVE TO NITROGEN MONOXIDE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Omniamed Co. Ltd (KR) | 2026-05-13 | — | — | EP | claimed |
| EP-4735001-A1 | METHODS FOR TREATING PERSISTENT OR CHRONIC IMMUNE THROMBOCYTOPENIA IN CHILDREN, ADOLESCENTS AND ADULTS BY ADMINISTERING (R)-2-[3-[4-AMINO-3-(2-FLUORO-4-PHENOXY- PHENYL)PYRAZOLO[3,4-D]PYRIMIDIN-1-YL]PIPERIDINE-1-CARBONYL]-4- METHYL-4-[4-(OXETAN-3-YL)PIPERAZIN-1-YL]PENT-2-ENENITRILE | Principia Biopharma Inc. (US) | 2026-05-06 | — | — | EP | claimed |
| WO-2026090174-A1 | COMPOSITIONS FOR TARGETED DELIVERY OF THERAPEUTIC AGENTS AND METHODS FOR THE SYNTHESIS AND USE THEREOF | BRYET US, INC. (US) | 2026-04-30 | — | — | WO | claimed |
| WO-2026090557-A1 | SYSTEMS AND METHODS FOR PROCESSING ISM AND MCAS CLINICAL TRIAL DATA | TELIOS PHARMA INC. (US) | 2026-04-30 | — | — | WO | claimed |
| US-20260102468-A1 | COMPOSITIONS AND METHODS FOR MARCO INHIBITION AND IMPROVED DRUG DELIVERY | UNIV TEXAS (US) | 2026-04-16 | — | — | US | claimed |
| US-20260097056-A1 | SYK ACTIVATORS AND INHIBITORS IN NEURODEGENERATIVE DISEASES | UNIV VIRGINIA PATENT FOUNDATION (US) | 2026-04-09 | — | — | US | claimed |
| US-20260076872-A1 | POLYMER VIALS WITH SUBSTANTIALLY FLAT BOTTOMS AND INJECTION STRETCH BLOW MOLDING METHODS FOR MAKING THE SAME | SIO2 MEDICAL PRODUCTS LLC (US) | 2026-03-19 | — | — | US | claimed |
| EP-4048260-B1 | COMBINATION OF SUBSTITUTED 4-AMINOISOINDOLINE-1,3-DIONE COMPOUNDS AND SECOND ACTIVE AGENTS FOR USE IN TREATING A HEMATOLOGICAL MALIGNANCY | CELGENE CORP (US) | 2026-03-11 | — | — | EP | claimed |
| EP-3277719-B1 | POLYPEPTIDES | SORRISO PHARMACEUTICALS INC (US) | 2022-03-16 | — | — | EP | claimed |
| US-11266700-B2 | Compositions and methods for treating immune disorders using immune modulating Lactococcus bacteria strains | EVELO BIOSCIENCES, INC. (US) | 2022-03-08 | — | — | US | claimed |
| US-20220054648-A1 | ANTIBODY-DRUG CONJUGATES AND USES THEREOF | IMMUNOMEDICS, INC. | 2022-02-24 | — | — | US | claimed |
| US-11253606-B2 | Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer | IMMUNOMEDICS, INC. (US) | 2022-02-22 | — | — | US | claimed |
| WO-2022035723-A1 | COMPOSITIONS, PANELS, AND METHODS FOR CHARACTERIZING CHRONIC LYMPHOCYTIC LEUKEMIA | THE BROAD INSTITUTE, INC. (US) | 2022-02-17 | — | — | WO | claimed |
| EP-3954373-A1 | NEOADJUVANT USE OF ANTIBODY-DRUG CONJUGATES | Immunomedics, Inc. (US) | 2022-02-16 | — | — | EP | claimed |
| WO-2022023759-A2 | METHODS OF PREPARING SOLID PARTICULATE MATERIALS | MICROPORE TECHNOLOGIES LIMITED (GB) | 2022-02-03 | — | — | WO | claimed |
| WO-2022020364-A1 | PREVOTELLA HISTICOLA STRAIN C AS AN ORAL THERAPY FOR INFLAMMATORY DISEASES | EVELO BIOSCIENCES, INC. (US) | 2022-01-27 | — | — | WO | claimed |
| WO-2022020326-A1 | VEILLONELLA PARVULA STRAIN AS AN ORAL THERAPY FOR NEUROINFLAMMATORY DISEASES | EVELO BIOSCIENCES, INC. (US) | 2022-01-27 | — | — | WO | claimed |
| EP-3942045-A1 | A DBAIT MOLECULE IN COMBINATION WITH KINASE INHIBITOR FOR THE TREATMENT OF CANCER | ONXEO (FR) | 2022-01-26 | — | — | EP | claimed |